Anzeige
Mehr »
Donnerstag, 30.10.2025 - Börsentäglich über 12.000 News
Weltweiter Kaliboom treibt Nachfrage - ACM positioniert sich im 93,5 Mrd. USD-Markt bis 2032!!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DDU5 | ISIN: SE0015244884 | Ticker-Symbol: P52
Frankfurt
30.10.25 | 15:29
0,143 Euro
-5,94 % -0,009
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
NEWBURY PHARMACEUTICALS AB Chart 1 Jahr
5-Tage-Chart
NEWBURY PHARMACEUTICALS AB 5-Tage-Chart

Aktuelle News zur NEWBURY PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiNewbury Pharmaceuticals AB: Newbury Pharmaceuticals year-end report September 2024 - August 202537 Quarter 4, June 2025 - August 2025Net revenue was 5 915 (21 123) tkr.EBITDA was -5 876 (2 402) tkr.Operating cash flow was -5 004 (130) tkr.Year-end period, September 2024 - August 2025Net revenue was...
► Artikel lesen
FrNewbury Pharmaceuticals AB: Newbury Pharmaceuticals Secures Generic Approval for Mirtazapin Newbury66Newbury Pharmaceuticals is pleased to announce the successful Marketing Authorization (MA) of Mirtazapin Newbury 15, 30 and 45 mg tablets in Sweden. Mirtazapin Newbury is a noradrenergic and specific...
► Artikel lesen
23.10.Newbury Pharmaceuticals AB: Newbury Pharmaceuticals Secures Generic Approval for Ivermectin Newbury77Newbury Pharmaceuticals is pleased to announce the successful Marketing Authorization (MA) of Ivermectin Newbury 10 mg/g cream in Denmark as the first country in a Scandinavian registration procedure....
► Artikel lesen
11.08.Newbury Pharmaceuticals AB: Newbury Pharmaceuticals Secures Generic Approval for Melatonin Newbury95Newbury Pharmaceuticals is pleased to announce the successful Marketing Authorization (MA) of Melatonin Newbury 2 mg prolonged-release tablets in Finland as the first country in a Nordic registration...
► Artikel lesen
09.07.Newbury Pharmaceuticals AB: Newbury Pharmaceuticals interim report September 2024 - May 2025154Quarter 3, March 2025 - May 2025Net revenue was 6 686 (1 386) tkr.EBITDA was -5 691 (-7 861) tkr.Operating cash flow was -5 787 (-10 182) tkr.Interim period, September 2024 - May 2025Net revenue was...
► Artikel lesen
NEWBURY PHARMACEUTICALS Aktie jetzt für 0€ handeln
16.04.Newbury Pharmaceuticals AB: Newbury Pharmaceuticals Secures Generic Approval for Pazopanib Newbury213Newbury Pharmaceuticals is pleased to announce the successful Marketing Authorization (MA) of Pazopanib Newbury tablets in Sweden as the first country in a Scandinavian registration procedure. Approvals...
► Artikel lesen
09.04.Newbury Pharmaceuticals AB: Newbury Pharmaceuticals interim report September 2024 - February 2025167Quarter 2, December 2024 - February 2025Net revenue was 12 434 (3 135) tkr.EBITDA was -973 (-4 147) tkr.Operating cash flow was -6 371 (-7 977) tkr.Interim period, September 2024 - February 2025Net...
► Artikel lesen
19.03.Newbury Pharmaceuticals AB: Newbury Pharmaceuticals expands its portfolio with four new products167Newbury Pharmaceuticals is strengthening its distribution partnership with an existing collaborator by adding four already registered products to its portfolio. The company plans to commercialize these...
► Artikel lesen
14.03.Newbury Pharmaceuticals AB: Newbury Pharmaceuticals Secures Approval for Macitentan film-coated tablets185Newbury Pharmaceuticals is pleased to announce the successful Marketing Authorization (MA) of Macitentan Newbury in Denmark as the first country in a Scandinavian registration procedure. Approvals in...
► Artikel lesen
24.01.Newbury Pharmaceuticals AB: Newbury Pharmaceuticals Secures Generic Approval for Pomalidomide capsules238Newbury Pharmaceuticals is pleased to announce the successful Marketing Authorization (MA) of Pomalidomide Newbury in Denmark as the first country in a Scandinavian registration procedure. Approvals...
► Artikel lesen
24.01.Newbury Pharmaceuticals AB: Newbury Pharmaceuticals interim report September 2024 - November 2024164Quarter 1, September 2024 - November 2024Net revenue was 6 538 (11 185) tkr.EBITDA was -3 759 (-2 734) tkr.Operating cash flow was 4 792 (-5 678) tkr.Cash position in the end of period was 19 431 (15...
► Artikel lesen
22.01.Newbury Pharmaceuticals AB: Newbury Pharmaceuticals Secures Generic Approval for Bosutinib tablets198Newbury Pharmaceuticals is pleased to announce the successful Marketing Authorization (MA) of Bosutinib Newbury in Norway as the first country in a Scandinavian registration procedure. Approvals in...
► Artikel lesen
12 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1